Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma
European Journal of Haematology · 2024
DOI: 10.1111/ejh.13964 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Shin Yeu Ong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Singapore General Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, B-Cell. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Although chimeric antigen receptor (CAR) T‐cell therapy has demonstrated remarkable efficacy in patients with chemo‐refractory B‐cell lymphoma, a significant portion is refractory or relapse. Resistance is a major barrier to improving treatment efficacy and long‐term survival in CAR T‐cell therapy, and clinicians have very limited tools to discriminate a priori patients who will or will not respond to treatment. While CD19‐negative relapses due to loss of target antigen is well described, it accounts for only about 30% of cases with treatment failure. Recent efforts have shed light on mechanisms of CD19‐positive relapse due to tumor intrinsic resistance, T‐cell quality/manufacturing, or CAR T‐cell exhaustion mediated by hostile tumor microenvironment. Here, we review the latest updates of preclinical and clinical trials to investigate the mechanisms of resistance and relapse post CAR T‐cell therapy in B cell lymphoma and discuss novel treatment strategies to overcome resistance as well as advances that are useful for a CAR T therapist to optimize and personalize CAR T‐cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Singapore General Hospital, Singapore, Singapore.
- Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Zitieren
APA
Ong, S. Y., Chen, Y., Tan, M. S. Y., Ho, A. Y. L., Hwang, W. Y. K., & Lim, F. L. W. I. (2024). Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.13964
Vancouver
Ong SY, Chen Y, Tan MSY, Ho AYL, Hwang WYK, Lim FLWI. Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma. European Journal of Haematology. 2024. doi:10.1111/ejh.13964
BibTeX
@article{Ong2024,
author = {Ong, Shin Yeu and Chen, Yunxin and Tan, Melinda Si Yun and Ho, Aloysius Yew Leng and Hwang, William Ying Khee and Lim, Francesca Lorraine Wei Inng},
title = {Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.13964}
}
EUVIMED